Diffusion Pharmaceuticals

130 articles with Diffusion Pharmaceuticals

• Diffusion Pharmaceuticals Begins Phase III Clinical Trial With TSC in Glioblastoma Multiforme

  12/27/2017

  The trial will screen 300 patients and enroll 264 in an effort to ensure that results from 236 patients will be available for analysis.

• Diffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity Rule

  11/20/2017

  The Company today announced that it has received notice from Nasdaq stating that the Company complies with the Nasdaq Capital Market Listing Rules requiring minimum stockholders’ equity of $2.5 million.

• Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

  11/13/2017

  We had cash, cash equivalents and a certificate of deposit totaling $11.2 million as of September 30, 2017.

• 

  Diffusion Pharma Receives Final FDA Protocol Guidance for Phase III Clinical Trial with TSC in Pa...

  10/17/2017

  The company expects to begin trial by year-end.

• Diffusion Pharma Names William Hornung Chief Business Officer

  8/23/2017

• Diffusion Pharma Reports Second Quarter 2017 Financial Results And Provides Business Update

  8/15/2017

• Diffusion Pharma Selects Contract Research Organization For Phase III Clinical Trial Of Lead Compound TSC For Inoperable GBM Brain Cancer

  7/31/2017

• Diffusion Pharma Achieves Drug Production Milestone For Planned Phase III Clinical Trial In Inoperable GBM Brain Cancer

  7/20/2017

• Diffusion Pharma Appoints Dr. Robert Ruffolo To Board Of Directors

  7/6/2017

• Diffusion Pharma Provides Corporate Highlights And Reports Financial First Quarter 2017 Results

  5/16/2017

• Diffusion Pharma Awarded U.S. Patent For TSC As Therapeutic In Five Hypoxia-Related Indications

  4/4/2017

• Diffusion Pharma Announces Closing Of Oversubscribed Private Placement

  4/3/2017

• Diffusion Pharma Provides Corporate Highlights And Reports 2016 Financial Results

  3/31/2017

• Diffusion Pharma’ TSC Phase I/II Glioblastoma Multiforme Clinical Trial Results Published In February 2017 Edition Of Journal Of Neurosurgery

  2/8/2017

• Diffusion Pharma Files Definitive Proxy Statement For Upcoming Special Meeting Of Stockholders

  12/12/2016

• Diffusion Pharma Provides Corporate Highlights and Reports Financial Third Quarter 2016 Results

  11/14/2016

• Diffusion Pharma Announces Uplisting To NASDAQ Capital Market

  11/8/2016

• Diffusion Pharma Establishes Scientific Advisory Board

  9/29/2016

• Diffusion Pharma Successfully Completes Animal Toxicity Studies In Preparation For Phase III Pivotal Trial Of TSC In New Diagnosed Glioblastoma Patients

  9/19/2016

• Diffusion Pharma To Present At 18th Annual Rodman & Renshaw Global Investment Conference

  9/9/2016